JOHN M. LEONARD - 01 Jan 2022 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role: President and CEO, Director
Signature: James Basta, attorney-in-fact
Issuer symbol: NTLA
Transactions as of: 01 Jan 2022
Transactions value $: -$279,852
Form type: 4
Filing time: 04 Mar 2022, 20:07:02 UTC
Previous filing: 01 Sep 2021
Next filing: 13 May 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NTLA	Common Stock	Options Exercise		+7.85K	+1.09%		727K	01 Jan 2022	Direct	F1
transaction	NTLA	Common Stock	Sale	-$280K	-2.49K	-0.34%	$112.26	725K	01 Jan 2022	Direct	F2
transaction	NTLA	Common Stock	Award	$0	+41K	+5.66%	$0.00	766K	01 Mar 2022	Direct	F3
holding	NTLA	Common Stock						58.4K	01 Jan 2022	By Trust	F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NTLA	Restricted Stock Unit	Options Exercise	$0	-7.85K	-25%	$0.00	23.5K	01 Jan 2022	Common Stock	7.85K		Direct	F1, F5
transaction	NTLA	Stock Option (right to buy)	Award	$0	+59.9K		$0.00	59.9K	01 Mar 2022	Common Stock	59.9K	$79.85	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2	Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 1, 2022.
F3	Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F4	Shares held by the John M. Leonard 2015 Irrevocable Trust.
F5	On March 3, 2021, the reporting person was granted 31,394 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments thereafter.
F6	This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.